Melbourne, Victoria, Australia
I am a pharmacist with an interest in emerging therapies. I have dedicated much of my career to advancing the quality use of medicines and am passionate about improving patient access to affordable treatment options in areas of high unmet need. My current focus is on delivering improved healthcare through advocacy, education and access to emerging therapies including cannabis-based medicines and psychedelic-assisted therapies.
Advancing healthcare through advocacy, education and access to emerging therapies including cannabis-based medicines and psychedelic-assisted therapies.
Led the Australian launch of Epidyolex, the first and only TGA-approved cannabidiol funded by the Australian Government on the Pharmaceutical Benefits Scheme (PBS) on 1st May 2021. In 2022, expanded access for patients through State funding and Federal reimbursement pathways. Responsible for the neurology portfolio, including GW Pharmaceutical products: Epidyolex and Sativex.
Led key pre-launch activities to bring Epidyolex (cannabidiol) to Australian patients.
Led educational initiatives and projects across multiple therapeutic areas including pain, oncology, neurology and hepatology. Responsible for emerging therapies and devices.